Pharma Focus Europe

Now more than ever, biotechnology companies face resource constraints and the perils of drug development. Strategic partnerships, fostering synergistic growth, become crucial. This article explores diverse partnership models, from licensing to equity, beyond mere finances. While replete with benefits, challenges like intellectual property and cultural disparities persist.

In an era where health-consciousness is on the rise and preventative medicine takes center stage, the concept of nutraceuticals emerges as a beacon of hope for individuals seeking holistic well-being. Coined by Stephen DE Felice in 1989, the term "nutraceutical"

Drug safety is a paramount concern for pharmaceutical companies worldwide. Ensuring the safety and efficacy of medications is not only a legal requirement but also a moral obligation towards patient welfare

Drug patents are central in the pharmaceutical field because they offer marketing privileges over drugs, foster technological advancement, and control the market. They drive the research expenditure, make research financially rewarding for firms, and determine the costs and availability of drugs.

Continuous biomanufacturing represents a paradigm shift in the production of biopharmaceuticals, offering unparalleled efficiency, flexibility, and quality control compared to traditional batch processes.

Navigating gene therapy regulations requires a comprehensive approach integrating scientific expertise, regulatory compliance, and ethical considerations. This article explores key compliance strategies, evolving regulatory trends like global harmonization,

Pharmaceutical viral vectors have emerged as powerful tools in gene therapy, vaccine development, and biotechnology research. The ability of viral vectors to deliver genetic material into target cells

Precision oncology trials are transforming cancer care by targeting genetic mutations for personalized treatments. This article discusses trial types, challenges like genomic profiling, key components for success, ethical considerations, emerging technologies (NGS, AI), and future directions like immunotherapy integration and early detection strategies.

The pharmaceutical industry is renowned for its stringent regulations, complex supply chains, and crucial emphasis on data integrity. In recent years, the emergence of blockchain technology has sparked considerable interest

This comprehensive overview explores the core aspects of pharmacological interventions in modern healthcare, covering mechanisms, classifications, and the impact on patient outcomes. Addressing challenges such as drug interactions, adherence, and resistance, the article emphasizes the importance of a patient-centered approach.

Recent developments in medical research have highlighted the potential of mRNA as a viable approach for addressing challenges in healthcare, particularly in combating infectious diseases and cancer

The changing regulatory landscape in Europe, spanning data protection, digital services, climate action, finance, healthcare, Brexit impact, consumer protection, AI ethics, taxation, and telecommunications, presents challenges and opportunities for businesses.

The pharmaceutical industry is experiencing a massive shift to new era phase known as Industry 4. 0, or less commonly known as Pharma 4. 0 in this context. In the middle of this transformational journey, we have Robotic Process Automation (RPA) as a tool that is disruptive in the way these pharmaceutical organizations are run and managed.

Recent years have seen a significant upheaval in the European pharmaceutical scene, marked by an unparalleled surge in biopharmaceutical prominence. This shift isn't fleeting but signifies a profound and enduring transformation. To fully grasp this paradigm shift, it's essential to explore the complex interplay of scientific advancements, market dynamics, regulatory frameworks, economic factors, and global competitiveness.

In Europe, there is a growing momentum around personalized medicine, an inventive method that customizes medical treatments based on individual characteristics. As progress in genomics and molecular diagnostics advances

Paracelsus in the 16th century established the principle of toxicology that the dose of a medicinal defines the difference between a remedy and a toxic effect.

Changes in public awareness, combined with changes in technology, are demanding innovative approaches to drive forward pharmacovigilance processes and the analysis of adverse event reporting.
https://www.pharmafocuseurope.com/information-technology/applying-ai-and-ml-to-optimise

The Role of European Pharma in Global Healthcare Advancements
International research also shows that European pharma industries contribute significantly to the global health system by providing for most of the drugs. https://www.pharmafocuseurope.com/articles/the-role-of-european-pharma-in-global-healthcare-advancements

Mass spectrometry (MS) is being rapidly applied to metabolomics because both the sensitivity and accuracy of analysis of metabolites can easily be achieved using this technique
https://www.pharmafocuseurope.com/articles/how-mass-spectrometers-are-transforming-the-study-of-metabolomics